Last reviewed · How we verify
Rimatil (BUCILLAMINE)
Bucillamine works by binding to copper ions in the body, reducing inflammation and oxidative stress.
Rimatil, also known as bucillamine, is a small molecule drug in the bucillamine class. It is a copper-chelating agent that works by binding to copper ions in the body, which can help to reduce inflammation and oxidative stress. Bucillamine is used to treat rheumatoid arthritis, a chronic autoimmune disorder that causes inflammation and pain in the joints. The commercial status of bucillamine is not specified, but it is likely to be patented or have limited generic availability. As a copper-chelating agent, bucillamine may have interactions with other medications that also affect copper levels in the body.
At a glance
| Generic name | BUCILLAMINE |
|---|---|
| Drug class | bucillamine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | discontinued |
Mechanism of action
Think of copper as a spark that can ignite a fire of inflammation in the body. Bucillamine is like a fire extinguisher that puts out that spark by binding to the copper and preventing it from causing damage. This helps to reduce pain and inflammation in people with rheumatoid arthritis.
Approved indications
Common side effects
- Lymphoproliferative disorder
- Interstitial lung disease
- Diffuse large B-cell lymphoma
- Epstein-Barr virus infection
- Pneumocystis jirovecii pneumonia
Key clinical trials
- A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) (PHASE3)
- Bucillamine in Treatment of Patients With COVID-19 (PHASE3)
- A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) (PHASE3)
- Bucillamine Phase 2 Trial in Patients With Cystinuria (PHASE2)
- Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout (PHASE2)
- Bucillamine Study of Holding Remission After Infliximab Dose-off (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rimatil CI brief — competitive landscape report
- Rimatil updates RSS · CI watch RSS